Burning Rock Biotech Limited ADR (BNR)
NASDAQ: BNRHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BNR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $139.63M
- EPS (TTM)
- -$0.80
- Dividend yield
- None
- 52-week range
- 6.79 – 41.72
- Day range
- 11.10 – 13.46
- Volume / Avg
- 27.87K / 36.51K
- Beta
- —
- Shares outstanding
- 8.81M
52-week range
BNR stock today
Shares of Burning Rock Biotech (BNR) finished lower on Nov 20 at $13.24, a drop of 0.60% or $0.08 per share, versus the S&P 500's 3.70% decline. At this level, BNR sits near the bottom of its 52-week range of $6.79 to $41.72: 68.3% below the high, set on Jan 22, 2026 and 95.0% above the low. BNR is down 34.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 7.1%.
Burning Rock Biotech has posted a net loss over the last twelve months (EPS of -$0.80), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Burning Rock Biotech
Company profileBurning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. Yusheng Han
- Headquarters
- Guangzhou
- Employees
- 667
- IPO year
- 2020
- Website
- brbiotech.com
Financial highlights
Full financialsIn fiscal 2025, Burning Rock Biotech generated $77.2 million in revenue, up 9.2% from fiscal 2024. Burning Rock Biotech reported a net loss of $7.9 million, compared with a loss of $47.5 million a year earlier. Gross margin was 74.7% (up from 70.3%) and operating margin -10.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $77.16M | $70.67M | $75.70M | $81.66M | $79.69M |
| Growth | +9.18% | -6.64% | -7.31% | +2.47% | +20.96% |
| Net income | $-7.92M | $-47.49M | $-92.07M | $-140.81M | $-125.02M |
| EPS (diluted) | — | — | — | — | $0.00 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 19, 2026
- EPS actual vs est.
- $-0.26 vs —
BNR news
All BNR newsBurning Rock Biotech peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TLSITriSalus Life Sciences Inc. | 2.32 | +6.67% | $143.14M | vs BNR |
| KEQUKewaunee Scientific Corporation | 33.55 | -2.75% | $97.14M | vs BNR |
| XGNExagen Inc. | 3.61 | -5.00% | $92.10M | vs BNR |
| BDSXBiodesix Inc. | 7.56 | -8.92% | $83.83M | vs BNR |
| SERASera Prognostics Inc. Class A | 1.81 | -4.23% | $71.98M | vs BNR |
| MDXHMDxHealth SA | 0.1074 | -8.52% | $10.25M | vs BNR |
| AMSAmerican Shared Hospital Services | 1.00 | -4.76% | $6.67M | vs BNR |
| ACONAclarion Inc. | 1.22 | -13.92% | $3.52M | vs BNR |
Indexes, lists and sector
Burning Rock Biotech stock FAQ
What is Burning Rock Biotech's stock price today?
BNR last traded at $13.24 as of Nov 20, 4:00 PM EST, down 0.60% on the day. Prices are delayed at least 15 minutes.
Does Burning Rock Biotech pay a dividend?
No. Burning Rock Biotech does not currently pay a regular cash dividend.
Who is Burning Rock Biotech's CEO?
Mr. Yusheng Han is the chief executive officer of Burning Rock Biotech Limited ADR, which has about 667 employees.
Has BNR ever split its stock?
Yes. The most recent BNR stock split was a 1-for-10 split on May 15, 2024.
What is the BNR 52-week high?
The 52-week high for BNR is $41.72 and the 52-week low is $6.79. The stock is currently 68.3% below its high.